Oncotarget

Research Papers:

Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancer

Florian C. Gaertner _, Khalil Halabi, Hojjat Ahmadzadehfar, Stefan Kürpig, Elisabeth Eppard, Charalambos Kotsikopoulos, Nikolaos Liakos, Ralph A. Bundschuh, Holger Strunk and Markus Essler

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:55094-55103. https://doi.org/10.18632/oncotarget.19049

Metrics: PDF 1985 views  |   HTML 4846 views  |   ?  


Abstract

Florian C. Gaertner1,*, Khalil Halabi1,*, Hojjat Ahmadzadehfar1, Stefan Kürpig1, Elisabeth Eppard1, Charalambos Kotsikopoulos1, Nikolaos Liakos1, Ralph A. Bundschuh1, Holger Strunk2 and Markus Essler1

1Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany

2Department of Radiology, University Hospital Bonn, Bonn, Germany

*These authors contributed equally to this work

Correspondence to:

Florian C. Gaertner, email: [email protected]

Keywords: PSMA, PET/CT, radionuclide therapy, prostate cancer, tumor load

Received: November 10, 2016     Accepted: June 26, 2017     Published: July 06, 2017

ABSTRACT

Radioligand therapy (RLT) with Lu-177-labeled PSMA-ligands is a new therapy option for prostate cancer. Biodistribution in normal tissues is of interest for therapy planning. We evaluated if the biodistribution of Ga-68-PSMA-11 is influenced by tumor load.

Results: In patients with high tumor load, SUVmean was reduced to 61.5% in the lacrimal glands, to 56.6% in the parotid glands, to 63.7% in the submandibular glands, to 61.3% in the sublingual glands and to 55.4% in the kidneys (p < 0.001). Further significant differences were observed for brain, mediastinum, liver, spleen and muscle. Total tracer retention was higher in patients with high tumor load (p < 0.05). SUV in lacrimal, salivary glands and kidneys correlated negatively with PSA.

Materials and Methods: 135 patients were retrospectively evaluated. SUV was measured in the lacrimal and salivary glands, brain, heart, liver, spleen, kidneys, muscle and bone. SUV was correlated with visual tumor load, total tracer retention and PSA.

Conclusions: Patients with high tumor load show a significant reduction of tracer uptake in dose-limiting organs. As similar effects might occur when performing RLT using Lu-177-labeled PSMA-ligands, individual adaptations of therapy protocols based on diagnostic PSMA PET imaging before therapy might help to further increase efficacy and safety of RLT.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19049